A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half. What doesn’t it ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

A new study published Thursday found that groundbreaking weight loss and diabetes medications also combat opioid-use disorder and alcohol misuse disorder. This is the second study this fall to suggest ...

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Academic notes while Ozempic might prevent overdoses, weight loss drug may not actually reduce or end substance use ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement ...

It is primary aim is to analyse how tirzepatide, sold by Eli Lilly under the brand name Mounjaro, reduces obesity and other ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...